Mark Mullen, MD

Dr Mullen is a fourth-year psychiatry resident at Creighton University.

Articles

Social Media Use in Older Adults May Promote Positive Psychosocial Outcomes

Meagan Kubista, MD;Orrin Chambers, DO;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

July 17th 2025

Social media use among older adults shows potential benefits for reducing loneliness and improving psychosocial well-being, though results vary across studies.

Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial

Joshua Robak, MD;Nishi Modi, MBBS;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

May 9th 2025

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Benzodiazepine Discontinuation Associated With Increased Mortality in Patients on Stable, Long-Term Benzodiazepines

Geena Sutherland, MD;Nancy Kartiko, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

April 16th 2025

New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

Clinical Features Associated With Response to Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression

Justin Allen, MD;Lalangi Marasinghe, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

March 19th 2025

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Xanomeline-Trospium as a Novel Agent for Treatment of Psychosis in Schizophrenia

Caitlin Leconte, MD;Albert Dickan, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

February 17th 2025

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

Evaluating the Efficacy of TMS for the Treatment of OCD

Tommy Sung, MD;Coralie Eilers, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

January 17th 2025

Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.

Assessing the Effectiveness of Treatments of Personality Disorders in the Community

Anvesh Jalasutram, MD;Ayse Coskun, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

December 13th 2024

Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

Exploring the Antisuicidal Effects of Lithium

Jesse Woo, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

November 14th 2024

A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

TMS for the Treatment of OCD

Tommy Sung, MD;Coralie Eilers, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

October 25th 2024

A new study shows that rTMS has moderate therapeutic effects on OCD severity.

The Safety of Psychostimulants or Atomoxetine for Patients With Psychotic Disorders

Nicholas Distefano, MD;Bransen Guild, DO;David Wilton, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

August 14th 2024

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

Zuranolone for the Treatment of Adults With Major Depressive Disorder

Joshua Robak, MD;Lior Hilsenrath, MD;Abigail Jaeger, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

July 12th 2024

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Longitudinal Study Looks at Risk of Cardiovascular Disease With Long-Term ADHD Medication Use

Masha Impallaria, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

May 25th 2024

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Treatment-Resistant Geriatric Depression: Augmenting or Switching an Antidepressant

Lalangi Marasinghe, MD;Anvesh Jalasutram, MD;Phil Ryan, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

April 17th 2024

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

Meagan Kubista, MD;Grethel Perez Meek, DO;Kyle Sramek, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

February 20th 2024

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.